Atogepant

Atogepant is a prescription medication used for preventive treatment of episodic and chronic migraine

• Atogepant is available under the following different brand names: Qulipta

Common side effects of Atogepant include:

• nausea
• constipation
• fatigue
• weight loss
• decreased appetite

Serious side effects of Atogepant include:

• hives
• difficulty breathing
• swelling of the face, lips, tongue, or throat
• severe dizziness
• elevated liver function tests

Rare side effects of Atogepant include:

• none 

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur as a result of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Tablet

• 10 mg
• 30 mg
• 60 mg

Episodic Migraine

Adult dosage

• 10 mg, 30 mg, or 60 mg orally once daily with or without food

Chronic Migraine

• 60 mg orally once daily with or without food

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Atogepant has severe interactions with no other drugs.
• Atogepant has serious interactions with the following drugs:
  • fostemsavir
  • leniolisib
  • trofinetide
• Atogepant has moderate interactions with at least 250 drugs.
• Atogepant has minor interactions with the following drugs:
  • acetazolamide
  • anastrozole
  • cyclophosphamide
  • lenvatinib
  • sotorasib

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, or if you have health questions or concerns.

Contraindications

• History of hypersensitivity to atogepant or any of its components

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Atogepant?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Atogepant?”

Cautions

• Hypersensitivity reactions
• Hypersensitivity reactions, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, reported
• Can occur days after administration
• If hypersensitivity occurs, discontinue the drug and institute appropriate therapy
• Drug interaction overview
  • Substrate of CYP3A4, OATP1B1, OATP1B3, and OAT1
  • Strong CYP3A4 inhibitors
    • Episodic migraine: Not to exceed 10 mg/day
    • Chronic migraine: Avoid use
    • Strong CYP3A4 inhibitors may significantly increase the exposure of atogepant
    • Moderate or weak CYP3A4 inhibitors
    • Monitor
    • No dosage adjustment is necessary
  • CYP3A4 inhibitors may increase the exposure of atogepant
    • Strong, moderate, or weak CYP3A4 inducers
    • Episodic migraine: Not to exceed 30 or 60 mg every Day
    • Chronic migraine: Avoid use
  • CYP3A4 inducers may decrease the exposure of atogepant
  • OATP inhibitors
    • Episodic migraine: Not to exceed 10 or 30 mg every Day
    • Chronic migraine: Not to exceed 30 mg every Day
    • OATP inhibitor may increase the exposure of atogepant

Pregnancy and Lactation

• There are no adequate data on the developmental risk associated with use in pregnant females
• Published data suggest migraine may increase the risk of preeclampsia and gestational hypertension during pregnancy
• Lactation
  • There are no data on the presence of atogepant in human milk, its effects on breastfed infants, or its effects on milk production
  • In lactating rats, oral dosing resulted in levels of atogepant in milk ~2-fold higher than that in maternal plasma
  • Consider the developmental and health benefits of breastfeeding along with the mother's clinical need and any potential adverse effects on the breastfed infant or from the underlying maternal condition